小剂量聚乙二醇干扰素α-2a联合利巴韦林抗病毒治疗失代偿期丙型肝炎肝硬化的临床效果观察

To Observe the Effect of Low-dose Peginterferon α-2a and Ribavirin Treatment of Decompensated Hepatitis C Cirrhosis

目的探讨针对失代偿期雨型肝炎肝硬化患者，观察选择小剂量聚乙二醇干扰素α-2a（Peg—IFNα-2a）＋利巴韦林完成治疗后获得的临床治疗。方法选择我院2013年1月～2015年1月失代偿期丙型肝炎肝硬化患者70例。通过随机数表法完成肝炎肝硬化患者的随机分组，C1组（观察组35例）：临床选择Peg-IFNα-2a＋利巴韦林进行治疗的方法：C2组（对照组35例）：临床选择常规治疗的方法。对比两种肝炎肝硬化患者在临床相关指标等方面表现出的差异。结果两组失代偿期丙型肝炎肝硬化患者完成临床治疗后，在ALT、ALB以及AST等方面，C1组优于C2组肝炎肝硬化患者（P〈0．05）；在肝脏纤维化指标方面，C1组优于C2组肝炎肝硬化患者（P〈0.05）。结论针对失代偿期丙型肝炎肝硬化患者，临床选择Peg—IFNα-2a＋利巴韦林的方法进行治疗，能够将患者的肝脏纤维化指标等进行有效改善，从而显著缓解肝炎肝硬化患者的临床症状表现，最终将失代偿期丙型肝炎肝硬化患者的生活质量有效提高。

Objective To study the patients with cirrhosis of the liver decompensation period of hepatitis c, observe choice interferon alpha 2 a small dose of polyethylene glycol （Peg - interferons alpha 2 a） and ribavirin completed after treatment for clinical treatment. Methods 70 patients with hepatitis c cirrhosis of the liver decompensation period from January 2013 to January 2015. Through the stochastic indicator method complete hepatitis cirrhosis patients randomized; C2 group of 35 cases （control group） ： clinical choose the method of conventional treatment, CI group （observation group of 35 cases） ： clinical choose Peg - interferons alpha - 2 a plus ribavirin treatment method. Compared to two kinds of hepatitis, liver cirrhosis patients in such aspects as clinically relevant indicators show the difference. Results Two groups of patients with cirrhosis of the liver decompensation period of hepatitis c after completion of clinical treatment in ALT, propagated and AST, C1 group is obviously better than the group of C2 hepatitis cirrhosis patients （P〈0.05）. In terms of liver fibrosis indexes, C1 group is obviously better than the group of C2 hepatitis cirrhosis patients （P〈0.05）. ConcLusion For patients with cirrhosis of the liver decompensation period of hepatitis c, clinical choose Peg - interferons alpha 2 a and method of ribavirin treatment, can effectively improve liver fibrosis indexes such as, in patients with significantly alleviate the clinical symptoms of patients with hepatitis cirrhosis of the liver, will eventually decompensation period of hepatitis c effective to improve the quality of life of patients with cirrhosis.